Brand Name :
Rebyota
Synonyms :
fecal microbiota, live-jslm, microbiota rectal
Class :
Gastrointestinal Agents
Dosage Forms & Strengths
Suspension-Rectal
150mL
Dose contains 1×108 and 5×1010 colony forming units (CFU)/mL of fecal microbes, including >1×105 CFU/mL of Bacteroides
clostridium difficile infection (CDI)
150
ml
Rectal administration
as a single dose
Note:
REBYOTA is not indicated for treatment of CDI, but Indicated for prevention of recurrence of CDI following antibiotic treatment for recurrent CDI
Administer 24-72 hours after last dose of antibiotics for CDI
Indicated to prevent Clostridioides difficile infection (CDI) recurrence in adults after antibiotic therapy for recurrent CDI (rCDI)
:
For three days, take four capsules orally every day
clostridium difficile infection (CDI)
Indicated to prevent Clostridioides difficile infection (CDI) recurrence in adults after antibiotic therapy for recurrent CDI (rCDI)
:
For three days, take four capsules orally every day
lansoprazole, amoxicillin, and clarithromycin
it decreases the efficacy of antibiotics
it decreases the efficacy of antibiotics
it decreases the efficacy of antibiotics
it decreases the efficacy of antibiotics
it decreases the efficacy of antibiotics
may decrease the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
hydrocodone/chlorpheniramine/pseudoephedrine
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may diminish the therapeutic effect of gastrointestinal agents
may diminish the therapeutic effect of gastrointestinal agents
may diminish the therapeutic effect of gastrointestinal agents
may diminish the therapeutic effect of gastrointestinal agents
may diminish the therapeutic effect of gastrointestinal agents
may decrease the therapeutic effects of opioid agonists
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of opioid agonists
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of anticholinergic agents
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Opioid Agonists
buprenorphine,long-acting injection
may decrease the therapeutic effect of Opioid Agonists
Gastrointestinal agents may lower the serum levels of the antibiotic fosfomycin
acetaminophen/doxylamine/dextromethorphan
may decrease the therapeutic effect of anticholinergic Agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
Frequency Defined
1-10%
Diarrhea (7.2%)
Abdominal pain (8.9%)
Flatulence (3.3%)
Abdominal distension (3.9%)
Nausea (3.3%)
Pregnancy warnings:
Pregnancy Category: Not absorbed systemically by the mother following rectal administration
Lactation:
Not absorbed systemically by the mother following rectal administration
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Generic Name: fecal microbiota, live-jslm
Why do we use fecal microbiota, live-jslm?
fecal microbiota, live-jslm is a Gastrointestinal Agent. It is indicated for the prevention of recurrence of CDI in individuals > 18 years following antibiotic treatment for recurrent CDI, and it is not indicated for the treatment of CDI.
.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
